title: The value of genomic analysis of breast cancer in drug development.
abstract: Improving the success rate and reducing the time that it takes to bring a new drug to the market represent important challenges for both academia and the pharmaceutical industry. High-throughput genomic analysis of cancer may assist streamlining this process through providing clinically relevant response markers, suggesting rational combination treatment strategies for biologically targeted agents and defining the next generation of therapeutic targets.
authors: Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA.
authors: Borbala
authors: B
authors: Szekely
authors: Lajos
authors: L
authors: Pusztai
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis; D055808:Drug Discovery; D005260:Female; D023281:Genomics; D006801:Humans; D017422:Sequence Analysis, DNA
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm